Corona-Virus

Oncology pharmaceutical Cleveland BioLabs, Inc. (NASDAQ: CBLI) develops immune-receptor activators for vaccines targeting various types of infection. Its vaccine adjuvant is currently in Phase 1 trials.



Cerus Corporation (NASDAQ: CERS) uses proprietary technology to inactivate the SARS strain, and it's looking to adapt its approach to the novel Wuhan strain.



Moderna Inc (NASDAQ: MRNA) received new funding from vaccine alliance CEPI to accelerate its work on a coronavirus vaccine, and it has joined forces with the Coalition for Epidemic Preparedness Innovations on a vaccine approach.



Aethlon Medical, Inc. (NASDAQ: AEMD) treats viral infections with its hemopurifier. The product boosts immune defenses by capturing otherwise poorly-detected circulating viruses. It is presently in clinical studies.



AstraZeneca plc (NYSE: AZN) said it had plans in place for an event such as this, but it awaits direction from the World Health Organization before acting.